Sr. Equity Analyst

CooperSurgical Fertility is the global leader in IVF and reproductive genetics, providing innovative products and services for every step in the ART journey. Alongside CooperSurgical Medical Devices, a leader in manufacturing trusted and innovative brands to help improve the health of women, babies and families worldwide, we are owned by The Cooper Companies. Building on the high-quality reputation of our legacy companies ORIGIO, SAGE, Humagen, The Pipette Company (TPC), K-Systems, Research Instruments (RI), Wallace®, LifeGlobal® and CooperGenomics, we provide a trusted system of consumables, equipment, technologies and genetic testing for the complete ART process. Operating as a seamless organization, with unmatched product breadth, scientific knowledge and geographical reach, our unified approach opens the door to extensive possibilities for the future. We can help drive and evolve innovation in line with customer needs; offering tailored product solutions, delivering world-class evidence-based training, and organizing expert-led workshops. As trusted brands, our products and services continue to meet stringent standards, and our high-quality manufacturing facilities and genetic testing laboratories have been specifically designed for the development of ART products and services. Working with experts and key opinion leaders in the field, we have dedicated research and development teams. They are continually developing innovative products, revolutionary technology and services using the latest clinical research, to help improve clinical workflows, processes, productivity and outcomes. In doing this, we aim to increase the quality of our partnerships with clinics across the globe and the quality of treatments for women and families.